Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABBV-154 (Primary) ; ABBV-154 (Primary)
Indications Crohn's disease
Focus Therapeutic Use
Acronyms AIM-CD
Sponsors AbbVie; AbbVie Germany

Most Recent Events

29 Sep 2023 This trial has been Completed in Netherlands, According to European Clinical Trials Database record.
16 Sep 2023 This trial has been Completed in Slovakia, According to European Clinical Trials Database record.
24 Aug 2023 This trial has been completed in Greece (End Date: 20 Jul 2023), According to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com